诺和诺德
NVO50.370USD
+0.190+0.38%
收盘 12/15, 16:00（美东）报价延迟15分钟
169.45B总市值
14.59市盈率 TTM
关于 诺和诺德 公司
诺和诺德是一家专注糖尿病护理的全球医疗健康公司，同时涉足药物的发现、研发、生产与行销。公司透过「糖尿病与肥胖护理」及「生物制药」两大业务运作。前者产品组合含胰岛素、GLP-1 受体激动剂（Ozempic、Wegovy、Rybelsus 等） 、胰高血糖素等蛋白质类疗法、蛋白质投递系统与注射针头，以及口服降糖药；后者聚焦血友病护理、生长激素补充及激素替代治疗。另有 Saxenda 专门针对临床肥胖症。主要品牌包含 NovoLog/NovoRapid、NovoLog Mix/NovoMix、Prandin/NovoNorm、NovoSeven、Norditropin、Vagifem 等。公司药品销往逾一百八十个国家，全球商业体系由北美与国际运营两大区域组成，透过临床研究、制造网络与市场渠道将疗法带给患者。
诺和诺德简介
公司代码NVO
公司名称Novo Nordisk A/S
上市日期May 17, 1974
CEODoustdar (Maziar Mike)
员工数量76302
证券类型Depository Receipt
年结日May 17
公司地址Novo Alle 1
城市BAGSVAERD
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家Denmark
邮编2880
电话4544448888
网址https://www.novonordisk.com/
公司代码NVO
上市日期May 17, 1974
CEODoustdar (Maziar Mike)
诺和诺德公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - People, Organisation & Corporate Affairs
Executive Vice President - People, Organisation & Corporate Affairs
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
其他
1.04B
8.92%
地区USD
名称
营收
占比
USA
6.53B
55.90%
Canada
2.50B
21.40%
Emerging Markets
1.15B
9.82%
APAC
852.83M
7.31%
Region China
651.28M
5.58%
业务
地区
业务USD
名称
营收
占比
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
其他
1.04B
8.92%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
其他
97.91%
持股股东
持股股东
占比
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
其他
97.91%
股东类型
持股股东
占比
Investment Advisor
4.66%
Investment Advisor/Hedge Fund
2.41%
Research Firm
0.92%
Hedge Fund
0.38%
Pension Fund
0.33%
Bank and Trust
0.20%
Insurance Company
0.19%
Family Office
0.02%
Family Office
0.02%
其他
90.87%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
2793
305.60M
9.08%
-33.91M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital International Investors
11.62M
0.35%
+2.11M
+22.18%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
12.58M
0.37%
+187.79K
+1.52%
Jun 30, 2025
Fidelity Management & Research Company LLC
12.93M
0.38%
+3.95M
+44.01%
Jun 30, 2025
Fisher Investments
11.00M
0.33%
-870.32K
-7.33%
Jun 30, 2025
Folketrygdfondet
10.09M
0.3%
+572.63K
+6.01%
Jun 30, 2025
Managed Account Advisors LLC
8.81M
0.26%
+195.59K
+2.27%
Jun 30, 2025
Fayez Sarofim & Co.
10.50M
0.31%
-708.84K
-6.32%
Jun 30, 2025
Everett Harris & Co.
6.39M
0.19%
-13.84K
-0.22%
Jun 30, 2025
Parametric Portfolio Associates LLC
6.23M
0.19%
+587.70K
+10.42%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
15.04%
VanEck Pharmaceutical ETF
14.55%
Amplify Weight Loss Drug & Treatment ETF
9.51%
The Opal International Dividend Income ETF
3.79%
TrueShares Low Volatility Equity Income ETF
3.21%
First Trust WCM International Equity ETF
2.68%
Invesco International Dividend Achievers ETF
1.8%
Putnam Focused Large Cap Value ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.05%
ActivePassive International Equity ETF
0.95%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比15.04%
VanEck Pharmaceutical ETF
占比14.55%
Amplify Weight Loss Drug & Treatment ETF
占比9.51%
The Opal International Dividend Income ETF
占比3.79%
TrueShares Low Volatility Equity Income ETF
占比3.21%
First Trust WCM International Equity ETF
占比2.68%
Invesco International Dividend Achievers ETF
占比1.8%
Putnam Focused Large Cap Value ETF
占比1.16%
SP Funds S&P World (ex-US) ETF
占比1.05%
ActivePassive International Equity ETF
占比0.95%
分红派息
近5年累计派现
21.09B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Aug 06, 2025
NVO.NB Interim Cash Dividend of gross USD 0.58432 paid on Aug 26, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 26, 2025
Aug 18, 2025
Feb 06, 2025
NVO.NB Final Cash Dividend of gross USD 1.142561 paid on Apr 08, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Apr 08, 2025
Mar 31, 2025
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Interim Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Final Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Interim Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Interim Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Final Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
查看更多
拆合股
公告日期
类型
比率
Aug 14, 2023
Split
1→2
公告日期
类型
比率
Aug 14, 2023
Split
1→2
常见问题
诺和诺德的前五大股东是谁？
诺和诺德 的前五大股东如下：
Capital International Investors持有股份：11.62M，占总股份比例：0.35%。
Loomis, Sayles & Company, L.P.持有股份：12.58M，占总股份比例：0.37%。
Fidelity Management & Research Company LLC持有股份：12.93M，占总股份比例：0.38%。
Fisher Investments持有股份：11.00M，占总股份比例：0.33%。
Folketrygdfondet持有股份：10.09M，占总股份比例：0.30%。
Capital International Investors持有股份：11.62M，占总股份比例：0.35%。
Loomis, Sayles & Company, L.P.持有股份：12.58M，占总股份比例：0.37%。
Fidelity Management & Research Company LLC持有股份：12.93M，占总股份比例：0.38%。
Fisher Investments持有股份：11.00M，占总股份比例：0.33%。
Folketrygdfondet持有股份：10.09M，占总股份比例：0.30%。
诺和诺德的前三大股东类型是什么？
诺和诺德 的前三大股东类型分别是：
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
有多少机构持有诺和诺德(NVO)的股份？
截至2025Q3，共有2793家机构持有诺和诺德的股份，合计持有的股份价值约为305.60M，占公司总股份的9.08%。与2025Q2相比，机构持股有所增加，增幅为-0.74%。
哪个业务部门对诺和诺德的收入贡献最大？
在FY2025Q2，Total GLP-1业务部门对诺和诺德的收入贡献最大，创收5.83B，占总收入的49.92%。
